Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Ahmet Emre Eskazan; Deniz Ozmen

doi:10.1080/17474086.2017.1339599

Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Expert Rev Hematol. 2017 Jul;10(7):583-586. doi: 10.1080/17474086.2017.1339599. Epub 2017 Jun 13.

Authors

Ahmet Emre Eskazan¹, Deniz Ozmen¹

Affiliation

¹ a Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology , Istanbul University , Istanbul , Turkey.

PMID: 28586242
DOI: 10.1080/17474086.2017.1339599

No abstract available

Keywords: Adverse event; bosutinib; chronic myeloid leukemia; dasatinib; first-line; imatinib; nilotinib; ponatinib; response; tyrosine kinase inhibitor.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

Antineoplastic Agents
Protein Kinase Inhibitors